

FEB 22 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Melissa Egbertson, Jeffrey Y. Melamed, H.
Marie Langford and Steven D. Young

Serial No. 10/500,972

Filed: July 2, 2004

For: HYDROXYNAPHTHYRIDINONE CARBOXAMIDES
USEFUL AS HIV INTEGRASE INHIBITORSArt Unit: Not Yet AssignedExaminer: Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Janice R. Egbertson Date 2/17/05

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney _____ For Applicant(s)

Reg. No. 32,951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3462

Date: February 17, 2005

COMPLETE IF KNOWN

FEB 22 2005

(use ~~8~~ many sheets as necessary)

Sheet

1

of

2

Attorney Docket Number

21021 YP

[illegible]


Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	5	WO	99/10347	A1	Neurogen Corporation	03/04/1999
	6	WO	02/04443	A2	Pharmacia & Upjohn Company	01/17/2002
	7	WO	95/00511	A1	The Boots Company PLC	01/05/1995
	8	WO	96/11198	A1	Knoll Aktiengesellschaft	04/18/1996
	9	WO	96/11199	A1	Knoll Aktiengesellschaft	04/18/1996
	10	WO	02/30930	A2	Merck & Co., Inc	04/18/2002
	11	WO	96/22990	A2	State of Oregon	08/01/1996

**Examiner
Signature**

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	10/500,972	
			Filing Date	July 2, 2004	
			First Named Inventor	Egbertson et al.	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21021 YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	12	Ratner, L., et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III", Nature, Vol. 313, pp. 277-284, (1985)
	13	Toh, H., et al., "Close Structural Resemblance Between Putative Polymerase of a Drosophila Transposable Genetic Element 17.6 and Pol Gene Product of Moloney Murine Leukaemia Virus", EMBO Journal, Vol. 4, pp. 1267-1272, (1985)
	14	Power, M.D., et al., "Nucleotide Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency Syndrome Retrovirus", Science, Vol. 231, pp. 1567-1572, (1986)
	15	Pearl, L.H., et al., "A Structural Model for the Retroviral Proteases", Nature, Vol. 329, pp. 351-354, (1987)
	16	Hart, E.P., J. "Naphthyridine. Part I. The Chemistry of 1:5-Naphthyridine", Journal of the Chemical Society, 1879-1882, (1954)
	17	Oakes, V., et al., "Polyazaphthalenes. Part V. Some 2:4-Disubstituted 1:5 Naphthyridines", Journal of the Chemical Society, pp 204-208, (1958)
	18	McCaustland, D.J., et al., "1,5-Naphthyridines. Synthesis of 7-Chloro-4-(4-diethylamino-1-methylbutylamino)-2-methoxy-1,5-naphthyridine and Related Compounds", Vol. 7, pp 467-463, (1970)
	19	Buckle, D.R., et al., "4-Hydroxy-3-nitro-2 quinolones and Related Compounds as Inhibitors of Allergic Reactions", Vol. 18, pp 726-732, (1975)
	20	Dunn, A.D., "The Synthesis of Novel Naphthyridines", Z. Chem., Vol. 30, pp. 20-21, (1990)
	21	Chen, J.L., et al., "Synthesis of Some Benzofuronaphthyridines and Benzofuronaphthyridine Derivatives", Journal of Heterocyclic Chemistry, Vol. 30, pp 909-912 (1993)
	22	Zografos, A.L., et al., "Chemoselective Cyclization of Aminonicotinic Acid Derivatives to 1,8-Naphthyridin-2-ones via a Potential Intramolecular Azadiene-Ketene Electrocyclization Reaction", Journal of Organic Chemistry, Vol. 66, pp 4413-4415, (2001)
	23	Bohn, B., et al., "Hammick Cyclizations Studies on the Mechanism of the Hammick Reaction", Heterocycles, Vol. 37, Issue 3, pp. 1731-1746, (1994)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003